Jul 27, 2021

Targeted therapy for BRAF-mutation-positive advanced NSCLC - Medivizor

Share In a nutshell This trial aimed to determine whether dabrafenib (Tafinlar) was effective and safe in treating BRAF-mutation-positive advanced NSCLC. The authors concluded that dabrafenib had some anticancer ability and tolerable side effects compared to other treatment options available for this type of cancer. Some background Genetic mutations (changes) in the BRAF gene can […]

Proceed to the page: http://linkis.com/KKG6k

Similar Articles Added Earlier

Similar Articles Added Today

Most Recent medivizor.com Articles

Latest Links Processed